Keymed Biosciences Inc. (HKG:2162)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
52.40
+4.40 (9.17%)
Mar 6, 2026, 4:08 PM HKT
Market Cap15.44B +69.7%
Revenue (ttm)955.73M +968.2%
Net Income-281.99M
EPS-1.07
Shares Out294.60M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,403,000
Average Volume1,401,131
Open47.94
Previous Close48.00
Day's Range47.64 - 52.65
52-Week Range33.30 - 80.00
Beta-0.10
RSI47.94
Earnings DateMar 27, 2026

About Keymed Biosciences

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China and internationally. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis, prurigo nodularis, and respiratory related indications. The company is also developing CMG901, a Claudin 18.2 antibody drug conjugate in Phase III trial to treat gas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1,469
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2162
Full Company Profile

Financial Performance

In 2024, Keymed Biosciences's revenue was 428.12 million, an increase of 20.91% compared to the previous year's 354.10 million. Losses were -515.24 million, 43.4% more than in 2023.

Financial numbers in CNY Financial Statements